← Eichor
Condition: Breast Cancer Nos Metastatic Recurrent Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Breast Cancer Nos Metastatic Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H
Phase 3 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT07533123A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
Phase 1/Phase 2 · 1 location(s) · BriaCell Therapeutics Corporation · NCT06471673A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07111832Chronic Toxicities Related to Treatment in Patients With Localized Cancer
NA · 1 location(s) · UNICANCER · NCT01993498A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06371274Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Nagoya City University · NCT07164976Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc
Phase 1 · 4 location(s) · Emory University · NCT06324240177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT04529044Neratinib in Combination With Ruxolitinib in Patients With mTNBC
EARLY_Phase 1 · 1 location(s) · Baylor Research Institute · NCT06008275A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Phase 1/Phase 2 · 1 location(s) · Shenzhen Majory Biotechnology Co., Ltd. · NCT07208149A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
Phase 2 · 1 location(s) · University of Utah · NCT05464082A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer
NA · 2 location(s) · JIANG LONGWEI · NCT06496724A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Trip
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06471205A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combinat
Phase 3 · 321 location(s) · AstraZeneca · NCT06103864PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Phase 1 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT04360941A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Phase 1/Phase 2 · 2 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06202261A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-lin
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07518173First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Phase 1 · 2 location(s) · General Oncology, Inc. · NCT04150042JS207 Combination Therapy in Triple-negative Breast Cancer
Phase 2 · 22 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07045311Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Phase 3 · 1 location(s) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · NCT06081959Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT06900647An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Pat
Phase 4 · 39 location(s) · AstraZeneca · NCT07357597Palbociclib and Pembrolizumab In Central Nervous System Metastases
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT02896335A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Meta
Phase 2 · 53 location(s) · Puma Biotechnology, Inc. · NCT06369285A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.